Nabriva Therapeutics to Present Lefamulin Data at ASM Microbe

Potential of Lefamulin to Treat Patients with CABP Against Backdrop of Increasing Bacterial Resistance Presented on Eight Posters DUBLIN, Ireland , May 31, 2018 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and

READ FULL TEXT

Leave a Reply

Your email address will not be published.